Homology Medicines, Inc.
Symbol: 0T6G.L
LSE
21.56
USDMarktpreis heute
-0.7390
P/E-Verhältnis
-0.0083
PEG-Verhältnis
283.62M
MRK Kapital
- 0.00%
DIV Rendite
Homology Medicines, Inc. (0T6G-L) Finanzberichte
Bilanz
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 82.7 | 175 | 155.9 | ||||||||
balance-sheet.row.short-term-investments | 0 | 43.4 | 141 | 47.5 | ||||||||
balance-sheet.row.net-receivables | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.other-current-assets | 0 | 1.3 | 6 | 36 | ||||||||
balance-sheet.row.total-current-assets | 0 | 83.9 | 181 | 191.9 | ||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 0.7 | 21.6 | 17.9 | ||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 25.8 | 2 | ||||||||
balance-sheet.row.tax-assets | 0 | 221.6 | 0 | 0 | ||||||||
balance-sheet.row.other-non-current-assets | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.total-non-current-assets | 0 | 222.2 | 47.5 | 19.8 | ||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.total-assets | 0 | 306.1 | 228.5 | 211.7 | ||||||||
balance-sheet.row.account-payables | 0 | 3.2 | 1.1 | 2.4 | ||||||||
balance-sheet.row.short-term-debt | 0 | 1.3 | 1.6 | 0.2 | ||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.long-term-debt-total | 0 | 49.4 | 11.9 | 5 | ||||||||
Deferred Revenue Non Current | 0 | -104.4 | 0 | 1.2 | ||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||
balance-sheet.row.other-current-liab | 0 | 7 | 18.7 | 11.4 | ||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 221.6 | 27.9 | 24.8 | ||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.capital-lease-obligations | 0 | 6.8 | 27.9 | 23.7 | ||||||||
balance-sheet.row.total-liab | 0 | 233.1 | 50.5 | 42.1 | ||||||||
balance-sheet.row.preferred-stock | 0 | 111.4 | 111.4 | 111.4 | ||||||||
balance-sheet.row.common-stock | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.retained-earnings | 0 | -542.1 | -429.1 | -424.1 | ||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | -0.4 | 0 | ||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 503.6 | 496.1 | 482.3 | ||||||||
balance-sheet.row.total-stockholders-equity | 0 | 73 | 178 | 169.7 | ||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 306.1 | 228.5 | 211.7 | ||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.total-equity | 0 | 73 | 178 | 169.7 | ||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||
Total Investments | 0 | 43.4 | 166.9 | 49.4 | ||||||||
balance-sheet.row.total-debt | 0 | 1.3 | 29.5 | 23.9 | ||||||||
balance-sheet.row.net-debt | 0 | -37.9 | -4.5 | -84.4 |
Kapitalflussrechnung
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -113 | -5 | -95.8 | ||||||||
cash-flows.row.depreciation-and-amortization | 0 | 0.6 | 2.6 | 9.5 | ||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | -19.2 | -38.8 | ||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 13.1 | 17.2 | ||||||||
cash-flows.row.change-in-working-capital | 0 | -7.2 | 3.4 | -41.8 | ||||||||
cash-flows.row.account-receivables | 0 | 0 | 0 | 0 | ||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | ||||||||
cash-flows.row.account-payables | 0 | 2.1 | -1 | -2.5 | ||||||||
cash-flows.row.other-working-capital | 0 | -9.3 | 4.3 | -39.3 | ||||||||
cash-flows.row.other-non-cash-items | 0 | 23.4 | -108.4 | 39.8 | ||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -0.2 | -1.3 | -2.4 | ||||||||
cash-flows.row.acquisitions-net | 0 | 0.6 | 130 | 48.4 | ||||||||
cash-flows.row.purchases-of-investments | 0 | -73.2 | -157.5 | -97.4 | ||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 174.2 | 65.5 | 49 | ||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | -48.4 | ||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 101.3 | 36.7 | -50.8 | ||||||||
cash-flows.row.debt-repayment | 0 | 0 | 0 | 0 | ||||||||
cash-flows.row.common-stock-issued | 0 | 0.2 | 0.6 | 52.2 | ||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||
cash-flows.row.other-financing-activites | 0 | 0 | 0.6 | 52.2 | ||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 0.2 | 0.6 | 52.2 | ||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | ||||||||
cash-flows.row.net-change-in-cash | 0 | 5.3 | -74.4 | -109 | ||||||||
cash-flows.row.cash-at-end-of-period | 0 | 39.3 | 34 | 108.4 | ||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 34 | 108.4 | 217.4 | ||||||||
cash-flows.row.operating-cash-flow | 0 | -96.2 | -113.7 | -109.8 | ||||||||
cash-flows.row.capital-expenditure | 0 | -0.2 | -1.3 | -2.4 | ||||||||
cash-flows.row.free-cash-flow | 0 | -96.5 | -114.9 | -112.1 |
Zeile der Gewinn- und Verlustrechnung
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 1.2 | 3.2 | 34 | ||||||||
income-statement-row.row.cost-of-revenue | 0 | 0.6 | 2.6 | 9.5 | ||||||||
income-statement-row.row.gross-profit | 0 | 0.6 | 0.6 | 24.4 | ||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | ||||||||
income-statement-row.row.operating-expenses | 0 | 92.7 | 133.9 | 120.4 | ||||||||
income-statement-row.row.cost-and-expenses | 0 | 93.3 | 136.5 | 129.9 | ||||||||
income-statement-row.row.interest-income | 0 | 5.6 | 3.2 | 0.2 | ||||||||
income-statement-row.row.interest-expense | 0 | 0 | 0 | 0 | ||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 5 | 134.5 | 0.2 | ||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | ||||||||
income-statement-row.row.total-operating-expenses | 0 | 5 | 134.5 | 0.2 | ||||||||
income-statement-row.row.interest-expense | 0 | 0 | 0 | 0 | ||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 0.6 | 2.6 | 9.5 | ||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||
income-statement-row.row.operating-income | 0 | -92.1 | -133.3 | -95.9 | ||||||||
income-statement-row.row.income-before-tax | 0 | -87.1 | 1.2 | -95.8 | ||||||||
income-statement-row.row.income-tax-expense | 0 | 0.3 | 0.7 | 0.5 | ||||||||
income-statement-row.row.net-income | 0 | -113 | -5 | -95.8 |
Häufig gestellte Frage
Wie hoch ist die Homology Medicines, Inc. (0T6G.L) Gesamtvermögen?
Homology Medicines, Inc. (0T6G.L) Gesamtvermögen ist 306119000.000.
Wie hoch ist der Jahresumsatz des Unternehmens?
Der Jahresumsatz ist N/A.
Wie hoch ist die Gewinnspanne des Unternehmens?
Die Gewinnmarge des Unternehmens ist 2.827.
Wie hoch ist der freie Cashflow des Unternehmens?
Der freie Cashflow ist -22.864.
Wie hoch ist die Nettogewinnspanne des Unternehmens?
Die Nettogewinnmarge ist 8.364.
Wie hoch sind die Gesamteinnahmen des Unternehmens?
Der Gesamtertrag ist 6.819.
Was ist der Homology Medicines, Inc. (0T6G.L) nettogewinn (reingewinn)?
Der Nettogewinn (Nettoeinkommen) ist -112961000.000.
Wie hoch ist die Gesamtverschuldung des Unternehmens?
Die Gesamtverschuldung ist 1318000.000.
Wie hoch ist der Betriebsaufwand?
Die Betriebsausgaben sind 92680000.000.
Wie hoch ist der Bargeldbestand des Unternehmens?
Die Unternehmensliquidität ist 0.000.